Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT02566304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor stem cell transplant may help stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Reducing the intensity of the chemotherapy and radiation may also reduce the side effects of the donor stem cell transplant.
Study identification
- NCT ID
- NCT02566304
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia in Remission
- Aplastic Anemia
- Chronic Myelomonocytic Leukemia
- Hodgkin Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Malignant Neoplasm
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Plasma Cell Myeloma
- Refractory Anemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Ring Sideroblasts
- Refractory Cytopenia With Multilineage Dysplasia
- Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
- Fludarabine Drug
- Total-Body Irradiation Radiation
- T Cell-Depleted Donor Lymphocyte Infusion Biological
- Cyclophosphamide Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Tacrolimus Drug
- Mycophenolate mofetil Drug
- Laboratory Biomarker Analysis Other
Drug · Radiation · Biological + 2 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2015
- Primary completion
- Feb 12, 2024
- Completion
- Feb 12, 2024
- Last update posted
- Apr 23, 2025
2015 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02566304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02566304 live on ClinicalTrials.gov.